MarketPR
STLDSteel Dynamics promotes six executives to support long-term growth strategyOct 20MACROSeptember CPI Jump to 3.7% Pressures Stocks Despite Long-Term GainsOct 20REGULATORYDisney acquires Character.AI assets via bankruptcy restructuringOct 20CRYPTOPlex Media Server flaws under active exploitationOct 20ENERGYRocks attacks El-Sayed's policy record in Fox News town hallOct 20ZIONZions Bancorporation reports $262 million in third-quarter net earningsOct 20SFBSServisFirst Bancshares reports 33% rise in third-quarter earnings per shareOct 20ACVACopart Completes Acquisition of ACV Auctions in Cash DealOct 20SUPNSupernus to Report Third Quarter 2026 Results on October 29Oct 20MACROFrench bond yields widen as cost-of-living protests intensifyOct 20STLDSteel Dynamics promotes six executives to support long-term growth strategyOct 20MACROSeptember CPI Jump to 3.7% Pressures Stocks Despite Long-Term GainsOct 20REGULATORYDisney acquires Character.AI assets via bankruptcy restructuringOct 20CRYPTOPlex Media Server flaws under active exploitationOct 20ENERGYRocks attacks El-Sayed's policy record in Fox News town hallOct 20ZIONZions Bancorporation reports $262 million in third-quarter net earningsOct 20SFBSServisFirst Bancshares reports 33% rise in third-quarter earnings per shareOct 20ACVACopart Completes Acquisition of ACV Auctions in Cash DealOct 20SUPNSupernus to Report Third Quarter 2026 Results on October 29Oct 20MACROFrench bond yields widen as cost-of-living protests intensifyOct 20
NewsMacro

Annexon Biosciences posts $0.28 per-share loss, missing analyst estimate by $0.04

A GAAP loss of $0.28 per share puts Annexon Biosciences (ANNX) in focus after the company's quarterly print came in $0.04 short of analyst expectations. The implied consensus stood at a $0.24 loss per share. The miss is clean and attributable, placing the result on the wrong side of the Street by a margin that markets will register.

By Grant HalloranNewsroomAugust 12, 20262 min read
Share

Key takeaways

  • Annexon Biosciences (ANNX) reported a GAAP loss of $0.28 per share for the quarter.
  • The result missed the analyst consensus estimate of a $0.24 per-share loss by $0.04.
  • The four-cent shortfall lands clearly on the unfavorable side of analyst expectations.
  • The article notes the source did not elaborate on pipeline updates or forward spending revisions.
  • Forward guidance is cited as the next definitive datapoint investors are watching.

A GAAP loss of $0.28 per share puts Annexon Biosciences (ANNX) in focus after the company's quarterly print came in $0.04 short of analyst expectations. The implied consensus stood at a $0.24 loss per share. The miss is clean and attributable, placing the result on the wrong side of the Street by a margin that markets will register.

The earnings print

Annexon Biosciences reported GAAP earnings per share of negative $0.28 for the period. Analyst consensus had modeled a loss of $0.24 per share, producing a four-cent shortfall. That gap lands on the unfavorable side with no ambiguity.

The tape's question on any loss-side print is whether the result matched analyst models. Here, it did not.

What the miss means for the setup

A four-cent shortfall on a per-share basis is specific enough to register. The setup for ANNX shares will depend on what accompanies the number. Pipeline updates and any revision to forward spending are the catalysts that typically shift the read on a print like this. The source does not elaborate on either.

Positioning around an earnings miss often reflects how much of the gap was already priced into the shares ahead of the report. The session reaction will clarify that more than the print alone.

What to watch

The next definitive datapoint for Annexon Biosciences is any forward guidance provided alongside or following the earnings release. Whether management holds prior targets or revises expectations in light of the reported quarter will be the read investors are waiting for.

Related reading

About this story

Filed by the newsroom of MarketPR on August 12, 2026. Source: MarketPR newsroom. Indicative figures are not investment advice.

←Back to the news index

More from the Newsroom

All stories →
01Macro

September CPI Jump to 3.7% Pressures Stocks Despite Long-Term Gains

The Bureau of Labor Statistics reported that the Consumer Price Index rose 0.6% in September, pushing the year-over-year inflation rate to 3.7%, up from 3.4% in the previous month. This data release moved markets, with the S&P 500 falling…

Renata Ostrowski2 min read
02Macro

French bond yields widen as cost-of-living protests intensify

Violent protests over the rising cost of living in France drove government bond prices lower, widening the gap between French and German 10-year bond yields to 146 basis points. The unrest heightened investor concerns regarding political…

Renata Ostrowski2 min read
03Macro

Anthropic taps nonprofits METR and SecureBio to help assess risks and safety practices

Anthropic announced Thursday that it is collaborating with the nonprofits METR and SecureBio to embed independent evaluators within its operations. The company is also in discussions with additional organizations, including Hugging Face…

Renata Ostrowski2 min read

Frequently asked

How much did Annexon Biosciences lose per share this quarter?

Annexon reported a GAAP loss of $0.28 per share for the period.

By how much did Annexon miss analyst estimates?

It missed by $0.04, as the analyst consensus called for a $0.24 per-share loss.

What was the analyst consensus estimate?

Analysts had modeled a loss of $0.24 per share.

What are investors watching next for ANNX?

Investors are watching for any forward guidance and whether management holds or revises prior targets in light of the reported quarter.

What could shift the market's read on this earnings miss?

Pipeline updates and any revision to forward spending are the catalysts that typically shift the read, though the source did not elaborate on either.